Scancell Files Amended F-4 for Neuphoria Merger; Exchange Ratio Set at ~0.37725 ADS per Share
Summary
Scancell's amended F-4 sets the Neuphoria merger terms: about 0.37725 Scancell ADSs plus a CVR per Neuphoria share, giving Neuphoria holders roughly 10.6% of the combined Nasdaq-listed company, contingent on a Neuphoria vote and at least $75 million of concurrent financing.
Key Events · M&A and Partnerships · SCNLD
-
Merger Terms Quantified in Amended F-4
Each Neuphoria share converts into approximately 0.37725 Scancell ADSs (3.77246 Scancell Shares) plus one CVR, implying about $4.55 per Neuphoria share at the $1.205 PIPE price.
-
Neuphoria Holders to Own ~10.6%
Post-closing, former Neuphoria stockholders hold about 10.6% of 193,225,001 total shares, PIPE investors about 16.8%, and existing Scancell holders about 53.7%.
-
$75M Financing Is a Closing Condition
Closing requires at least $75 million of aggregate proceeds from the $39.1 million PIPE, the $21.0 million UK offerings already closed, and the up-to-$25.0 million BlackRock/Kreos debt facility, of which $7.0 million was drawn November 2, 2026.
-
Closing Net Cash Cushion Is Thin
Neuphoria estimates closing net cash of about $11.8 million as of November 10, 2026 against the $10 million minimum condition, leaving roughly $1.8 million of headroom.
Analysis · SCNLD · Life Sciences
The amended registration statement and proxy for the all-stock reverse merger that will make Neuphoria a subsidiary of Scancell, which then lists ADSs on Nasdaq under 'SCLT', now puts numbers on the deal. Neuphoria holders receive roughly 0.37725 Scancell ADSs (3.77246 Scancell Shares) per share plus a CVR, implying about $4.55 per Neuphoria share at the $1.205 PIPE price, and they will own roughly 10.6% of the combined company. Closing is gated on Neuphoria stockholder approval, a $75 million minimum financing, and Neuphoria holding at least $10 million of closing net cash; management estimates about $11.8 million, a thin cushion. The concurrent financing is large relative to Scancell: $39.1 million PIPE, $21.0 million UK offerings already closed, and up to $25.0 million of BlackRock/Kreos debt, with $7.0 million drawn November 2, 2026. Existing Scancell holders are diluted to about 53.7% of shares, and the debt carries 10.50%-10.95% interest plus warrants and a 117p conversion. Two things decide whether this closes: the vote and the financing.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SCNLD was trading at $1.06 on OTC in the Life Sciences sector, with a market capitalization of approximately $128.5M. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.